Kathryn A. Taubert, Ph.D., who has given nearly 25 years of service to the AHA, most recently in the role of Senior Scientist and Special Assistant to the CSO, will be moving to the World Heart Federation in Geneva, Switzerland in early April as Senior Science Officer.
The new position will allow her to fulfill a long time dream of living and working in Europe, as she will work from their offices in Geneva, and it will also let her work with underdeveloped and developing countries, another long time wish.
She plans to continue to have involvement with the AHA as a council member, and she will retain her current faculty position as Adjunct Professor of Physiology at the University of Texas Southwestern Medical School in Dallas.
Dr. Taubert joined the AHA in 1985 as a staff scientist, and worked as Director of Cardiovascular Science and then as Vice-President of the Science and Medicine Department before taking up her current role in 2004.
Many of the processes we now take for granted in science at AHA were developed under Dr. Taubert’s supervision. She streamlined the peer review process for council-generated scientific statements, developed a formal process for internal science review of news releases and patient/public educational materials, and helped develop the Clinical Science Committee (forerunner of the Manuscript Oversight Committee, which she has staffed since its inception).
At one time or another, Dr. Taubert has served as staff scientist for the majority of AHA Councils, and has been the staff scientist to CVDY since 1985. She was elected a FAHA by the Clinical Cardiology Council (1998) and by CVDY (inaugural fellow, 2003). The Councils have also recognized her with their Distinguished Achievement Award (presented by CVDY) in 2000, and the Women in Cardiology Mentoring Award from the Council on Clinical Cardiology in 2001.
Dr. Taubert is well-known for her great skill in assisting writing groups for scientific statements, having worked with more than 200 groups over the years, and has been co-author on statements and guidelines related to endocarditis, rheumatic fever, Kawasaki disease, pediatric heart disease, women and heart disease, NSAIDs, and the primary and secondary prevention of CVD, as well as the recent “Preventing Cancer, Cardiovascular Disease, and Stroke. A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association”, which was the initial science statement of our current partnership with ACS and ADA. She is nationally and internationally recognized as an expert in endocarditis and Kawasaki disease, and continues to give invited talks on these topics as well as on women and heart disease and on the modeling of preventive care at AHA, ACC, and other national and international meetings.